BioAmber Inc. announced unaudited consolidated earnings results for the third quarter ended September 30, 2017. For the quarter, the company's product sales were $3,301,000 against $3,661,000 a year ago, the decrease was mainly driven by a decrease in volume sold, slightly offset by an increase in the average selling price. Operating loss was $8,076,000 against $6,572,000 a year ago. Loss before income taxes was $7,854,000 against $6,719,000 a year ago. Net loss attributable to shareholders of the company was $7,050,000 or $0.16 per basic share against $6,158,000 or $0.21 per basic share a year ago. Net cash used in operating activities was $24,537,000 against $33,101,000 a year ago. Acquisition of property and equipment and intangible asset, net of disposals was $722,000 against $540,000 a year ago. Adjusted net loss attributable to shareholders of the company was $9.4 million, or a loss of $0.21 per share, compared to $7.4 million, or a loss of $0.26 per share, for the three months ended September 30, 2016.

For the nine months, the company reported revenues increased by 25% to $9.5 million from $7.6 million last year.

For the fourth quarter, the company expects sales in fourth quarter are robust, and that The company expects that fourth quarter will be strong.